Publications by authors named "Camilla Hage"
Aims: Guidelines recommend immediate initiation of all four class I guideline-directed medical therapies, renin-angiotensin system inhibitors (RASI) or angiotensin receptor-neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) following the diagnosis of heart failure (HF) with reduced ejection fraction (HFrEF). The extent to which this occurs in new-onset HFrEF is unclear. We assessed guideline-recommended therapies during the first year following a HFrEF diagnosis.
View Article and Find Full Text PDFExamining the clinical role and educational preparation of heart failure nurses across Europe. A survey of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP) of the ESC.
Eur J Heart Fail
November 2024
Aims: To describe the clinical practice and educational preparation of heart failure (HF) nurses across Europe and determine the key differences between countries.
Methods And Results: A survey tool was developed, in English, by the Heart Failure Association Patient Care committee of the European Society of Cardiology (ESC). It was translated into eight languages, before electronically disseminated by nurse ambassadors, presidents of HF national societies and through social media.
Aims: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are prevalent comorbidities associated with significant morbidity/mortality. We assessed prevalence of, patient profiles and outcomes associated with COPD across the ejection fraction (EF) spectrum.
Methods: HF patients enrolled in the Swedish HF registry between 2005 and 2021 were considered.
Article Synopsis
- - The study investigates the differences in gene expression between epicardial adipose tissue (EAT) around the heart and subcutaneous adipose tissue (SAT) in patients undergoing heart surgery, revealing distinct gene clusters linked to heart failure (HF) characteristics.
- - Researchers identified 17 gene clusters in EAT, with seven showing significant correlations to heart failure measures, indicating a unique role that EAT may play in heart dysfunction, especially related to inflammation and tissue repair.
- - The findings emphasize the different impacts of EAT and SAT on heart health, suggesting that EAT could influence the progression of heart failure, which necessitates further studies to better understand these connections.
Article Synopsis
- - The SPIRRIT-HFpEF trial aims to evaluate the benefits of mineralocorticoid receptor antagonists (MRAs) like spironolactone for patients with heart failure and preserved or mildly reduced ejection fraction, focusing on a cost-effective registry-based approach.
- - This multicenter trial involves randomizing patients to receive either MRAs with usual care or just usual care, measuring outcomes such as cardiovascular deaths and heart failure-related hospitalizations over a 6-year enrollment period, with a target of around 2400 patients.
- - The study’s findings will provide insights into the effectiveness of MRAs for heart failure patients and demonstrate the viability of using pragmatic, registry-based trials for research in chronic conditions.
Aims: The detailed sub-categories of death and hospitalization, and the impact of comorbidities on cause-specific outcomes, remain poorly understood in heart failure (HF) with preserved ejection fraction (HFpEF). We sought to evaluate rates and predictors of cardiovascular (CV) and non-CV outcomes in HFpEF.
Methods: The Karolinska-Rennes study was a bi-national prospective observational study designed to characterize HFpEF (ejection fraction ≥45%).
Aims: The prevalence of iron deficiency (ID) in newly diagnosed heart failure (HF) and the progression of ID in patients after initiation of HF therapy are unknown. We aimed to describe the natural trajectory of ID in patients with new onset HF during the first year after HF diagnosis, assessing associations between ID, clinical factors, and quality of life (QoL).
Methods And Results: A prospective cohort of patients with new onset HF in hospitals or outpatient clinics at five major hospitals in Stockholm, Sweden, during 2015-2018 were analysed with clinical assessment, electrocardiogram, blood samples including iron levels, Minnesota living with heart failure questionnaire (MLHFQ), and echocardiogram at baseline and after 12 months.
Aims: We assessed eligibility for omecamtiv mecarbil (OM) in a real-world cohort with heart failure with reduced ejection fraction (HFrEF) according to the selection criteria of the GALACTIC-HF trial (trial scenario) and selected trial´s criteria more likely to impact real-world use (pragmatic scenario).
Methods And Results: We included 31,015 patients with HFrEF lasting ≥3 months and registered in the Swedish HF registry between 2000-2021. Trial eligibility was calculated by applying all the GALACTIC-HF selection criteria.
New or mild heart failure (HF) is mainly caused by left ventricular dysfunction. We hypothesised that gene expression differ between the left (LV) and right ventricle (RV) and secondly by type of LV dysfunction. We compared gene expression through myocardial biopsies from LV and RV of patients undergoing elective coronary bypass surgery (CABG).
View Article and Find Full Text PDFBackground: Hospitalization for heart failure (HHF) is associated with poor postdischarge outcomes but the role of time since most recent HHF and potential treatment interactions are unknown. We aimed to assess history of and time since previous HHF, associations with composite of cardiovascular (CV) death and total HHF, first HHF and interactions with randomization to spironolactone, in heart failure with preserved ejection fraction.
Methods And Results: We assessed these objectives using uni- and multivariable regressions and spline analyses in TOPCAT-Americas.
Article Synopsis
- Echocardiographic strain imaging is important for assessing heart function, and deep learning (DL) algorithms can automate its interpretation.
- An automated DL-based algorithm for measuring left ventricular strain was trained and validated using datasets from various studies, showing high accuracy compared to manual measurements.
- The study concluded that DL algorithms can interpret echocardiographic strain images effectively, potentially improving accessibility to cardiac assessments.
Background: There is a paucity of data on the clinical characteristics, management, and outcomes of women compared with men with heart failure in low-income and middle-income countries compared with high-income countries. We examined sex differences in risk factors, clinical characteristics, and treatments, and prospectively assessed the risk of heart failure hospitalisation and mortality in patients with heart failure in 40 high-income, middle-income, and low-income countries.
Methods: Participants aged 18 years or older with heart failure were enrolled from Dec 20, 2016, to Sept 9, 2020 in the prospective Global Congestive Heart Failure (G-CHF) study from 257 centres in 40 high-income, middle-income, and low-income countries.
Aim: Acyl ghrelin increases cardiac output (CO) in heart failure with reduced ejection fraction (HFrEF). This could impair the right ventricular-pulmonary arterial coupling (RVPAC), both through an increased venous return and right ventricular afterload. We aim to investigate if acyl ghrelin increases CO with or without worsening the right-sided haemodynamics in HFrEF assessed by RVPAC.
View Article and Find Full Text PDFAims: In heart failure with preserved ejection fraction (HFpEF), regional heterogeneity of clinical phenotypes is increasingly recognized, with coronary microvascular dysfunction (CMD) potentially being a common shared feature. We sought to determine the regional differences in clinical characteristics and prevalence of CMD in HFpEF.
Methods And Results: We analysed clinical characteristics and CMD in 202 patients with stable HFpEF (left ventricular ejection fraction ≥40%) in Finland, Singapore, Sweden, and United States in the multicentre PROMIS-HFpEF study.
Aims: Mineralocorticoid receptor antagonists (MRAs) improve outcomes in heart failure with reduced ejection fraction (HFrEF) but remain underused and are often discontinued especially in patients with chronic kidney disease (CKD) due to concerns on renal safety. Therefore, in a real-world HFrEF population we investigated the safety of MRA use, in terms of risk of renal events, any mortality and any hospitalization, across the estimated glomerular filtration rate (eGFR) spectrum including severe CKD.
Methods And Results: We analysed patients with HFrEF (ejection fraction <40%), not on dialysis, from the Swedish Heart Failure Registry.
Aims: Although trials have proven the group-level effectiveness of various therapies for heart failure with reduced ejection fraction (HFrEF), important differences in absolute effectiveness exist between individuals. We developed and validated the LIFEtime-perspective for Heart Failure (LIFE-HF) model for the prediction of individual (lifetime) risk and treatment benefit in patients with HFrEF.
Methods And Results: Cox proportional hazards functions with age as the time scale were developed in the PARADIGM-HF and ATMOSPHERE trials (n = 15 415).
Article Synopsis
- The Heart Failure Association of the European Society of Cardiology aims to enhance medical treatments for heart failure patients by analyzing specific patient profiles.
- Researchers studied heart failure patients in Sweden from 2013 to 2021, identifying 93 profiles based on factors like kidney function and heart rhythm, finding that specific groups had higher risks of cardiovascular issues.
- The study suggests that most patients fit easily into recognizable profiles and highlights the potential for targeted treatment strategies based on these profiles to improve outcomes.
Article Synopsis
- Most heart failure (HF) studies have focused on high-income nations, leaving a gap in data from middle- and low-income countries regarding HF causes and management.
- The study analyzed 23,341 participants across various economic levels over two years, finding ischemic heart disease as the leading cause of HF.
- Results showed better treatment and lower mortality rates in high-income countries, with significant disparities in medication use and hospitalization rates compared to lower-income nations.
Background: Systemic microvascular dysfunction and inflammation are postulated to play a pathophysiologic role in heart failure with preserved ejection fraction (HFpEF).
Objectives: This study aimed to identify biomarker profiles associated with clinical outcomes in HFpEF and investigate how inhibition of the neutrophil-derived reactive oxygen species-producing enzyme, myeloperoxidase, affects these biomarkers.
Methods: Using supervised principal component analyses, the investigators assessed the associations between baseline plasma proteomic Olink biomarkers and clinical outcomes in 3 independent observational HFpEF cohorts (n = 86, n = 216, and n = 242).
Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes - from the ESC-HFA EORP Heart Failure Long-Term Registry.
Eur J Heart Fail
September 2023
Aims: To comprehensively assess hyponatraemia in acute heart failure (AHF) regarding prevalence, associations, hospital course, and post-discharge outcomes.
Methods And Results: Of 8298 patients in the European Society of Cardiology Heart Failure Long-Term Registry hospitalized for AHF with any ejection fraction, 20% presented with hyponatraemia (serum sodium <135 mmol/L). Independent predictors included lower systolic blood pressure, estimated glomerular filtration rate (eGFR) and haemoglobin, along with diabetes, hepatic disease, use of thiazide diuretics, mineralocorticoid receptor antagonists, digoxin, higher doses of loop diuretics, and non-use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers.